Literature DB >> 30177781

Body Mass Index, Diabetes and Intrahepatic Cholangiocarcinoma Risk: The Liver Cancer Pooling Project and Meta-analysis.

Jessica L Petrick1, Jake E Thistle1, Anne Zeleniuch-Jacquotte1, Xuehong Zhang1, Jean Wactawski-Wende1, Alison L Van Dyke1, Meir J Stampfer1,1,1, Rashmi Sinha1, Howard D Sesso1,1, Catherine Schairer1, Lynn Rosenberg1, Thomas E Rohan1, Kim Robien1, Mark P Purdue1, Jenny N Poynter1, Julie R Palmer1, Christina C Newton1, Martha S Linet1, Linda M Liao1, I-Min Lee1,1, Jill Koshiol1, Cari M Kitahara1, Jonathan N Hofmann1, Barry I Graubard1, Edward Giovannucci1,1,1, Michael J Gaziano1,1, Susan M Gapstur1, Neal D Freedman1, Dawn Q Chong1, Andrew T Chan1,1,1, Julie E Buring1,1, Laura Beane E Freeman1, Peter T Campbell1, Katherine A McGlynn1.   

Abstract

OBJECTIVE: Obesity and diabetes are associated with an increased liver cancer risk. However, most studies have examined all primary liver cancers or hepatocellular carcinoma, with few studies evaluating intrahepatic cholangiocarcinoma (ICC), the second most common type of liver cancer. Thus, we examined the association between obesity and diabetes and ICC risk in a pooled analysis and conducted a systematic review/meta-analysis of the literature.
DESIGN: For the pooled analysis, we utilized the Liver Cancer Pooling Project, a consortium of 13 US-based, prospective cohort studies with data from 1,541,143 individuals (ICC cases n = 414). In our systematic review, we identified 14 additional studies. We then conducted a meta-analysis, combining the results from LCPP with results from the 5 prospective studies identified through September 2017.
RESULTS: In the LCPP, obesity and diabetes were associated with a 62% [Hazard Ratio (HR) = 1.62, 95% Confidence Interval (CI): 1.24-2.12] and an 81% (HR = 1.81, 95% CI: 1.33-2.46) increased ICC risk, respectively. In the meta-analysis of prospectively ascertained cohorts and nested case-control studies, obesity was associated with a 49% increased ICC risk [Relative Risk (RR) = 1.49, 95% CI: 1.32-1.70; n = 4 studies; I2 = 0%]. Diabetes was associated with a 53% increased ICC risk (RR = 1.53, 95% CI: 1.31-1.78; n = 6 studies). While we noted heterogeneity between studies (I2 = 67%) for diabetes, results were consistent in subgroup analyses. Results from hospital-based case-control studies (n = 9) were mostly consistent, but these studies are potentially subject to reverse causation.
CONCLUSIONS: These findings suggest that obesity and diabetes are associated with increased ICC risk, highlighting similar etiologies of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. However, additional prospective studies are needed to verify these associations.

Entities:  

Mesh:

Year:  2018        PMID: 30177781      PMCID: PMC6521884          DOI: 10.1038/s41395-018-0207-4

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  64 in total

1.  Dietary assessment of older Iowa women with a food frequency questionnaire: nutrient intake, reproducibility, and comparison with 24-hour dietary recall interviews.

Authors:  R G Munger; A R Folsom; L H Kushi; S A Kaye; T A Sellers
Journal:  Am J Epidemiol       Date:  1992-07-15       Impact factor: 4.897

2.  Obesity and the risk of cholangiocarcinoma: a meta-analysis.

Authors:  Jun-Shan Li; Tian-Jie Han; Nie Jing; Lei Li; Xiao-Hua Zhang; Feng-Zhen Ma; Ji-Yong Liu
Journal:  Tumour Biol       Date:  2014-04-13

3.  Changing patterns in the incidence of esophageal and gastric carcinoma in the United States.

Authors:  S S Devesa; W J Blot; J F Fraumeni
Journal:  Cancer       Date:  1998-11-15       Impact factor: 6.860

4.  Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma.

Authors:  Satoshi Yamamoto; Shoji Kubo; Seikan Hai; Takahiro Uenishi; Takatsugu Yamamoto; Taichi Shuto; Shigekazu Takemura; Hiromu Tanaka; Osamu Yamazaki; Kazuhiro Hirohashi; Takashi Tanaka
Journal:  Cancer Sci       Date:  2004-07       Impact factor: 6.716

5.  The metabolic syndrome and risk factors for biliary tract cancer: a case-control study in China.

Authors:  Qiao Wu; Xiao-Dong He; Lan Yu; Wei Liu; Lian-Yuan Tao
Journal:  Asian Pac J Cancer Prev       Date:  2012

6.  Global estimates of the prevalence of diabetes for 2010 and 2030.

Authors:  J E Shaw; R A Sicree; P Z Zimmet
Journal:  Diabetes Res Clin Pract       Date:  2009-11-06       Impact factor: 5.602

7.  Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study.

Authors:  Tania M Welzel; Barry I Graubard; Hashem B El-Serag; Yasser H Shaib; Ann W Hsing; Jessica A Davila; Katherine A McGlynn
Journal:  Clin Gastroenterol Hepatol       Date:  2007-08-06       Impact factor: 11.382

8.  Oxidative stress and inflammation: essential partners in alcoholic liver disease.

Authors:  Aditya Ambade; Pranoti Mandrekar
Journal:  Int J Hepatol       Date:  2012-03-01

9.  Interactive role of diabetes mellitus and female sex in the risk of cholangiocarcinoma: A population-based nested case-control study.

Authors:  Yan-Jiun Huang; Alexander Th Wu; Hung-Yi Chiou; Ming-Tsang Chuang; Tzu-Ching Meng; Li-Nien Chien; Yun Yen
Journal:  Oncotarget       Date:  2017-01-24

10.  Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: A population-based study in SEER-Medicare.

Authors:  Jessica L Petrick; Baiyu Yang; Sean F Altekruse; Alison L Van Dyke; Jill Koshiol; Barry I Graubard; Katherine A McGlynn
Journal:  PLoS One       Date:  2017-10-19       Impact factor: 3.240

View more
  21 in total

1.  Anthropometric Risk Factors for Cancers of the Biliary Tract in the Biliary Tract Cancers Pooling Project.

Authors:  Sarah S Jackson; Alison L Van Dyke; Bin Zhu; Ruth M Pfeiffer; Jessica L Petrick; Hans-Olov Adami; Demetrius Albanes; Gabriella Andreotti; Laura E Beane Freeman; Amy Berrington de González; Julie E Buring; Andrew T Chan; Yu Chen; Gary E Fraser; Neal D Freedman; Yu-Tang Gao; Susan M Gapstur; J Michael Gaziano; Graham G Giles; Eric J Grant; Francine Grodstein; Patricia Hartge; Mazda Jenab; Cari M Kitahara; Synnove F Knutsen; Woon-Puay Koh; Susanna C Larsson; I-Min Lee; Linda M Liao; Juhua Luo; Emma E McGee; Roger L Milne; Kristine R Monroe; Marian L Neuhouser; Katie M O'Brien; Ulrike Peters; Jenny N Poynter; Mark P Purdue; Kim Robien; Dale P Sandler; Norie Sawada; Catherine Schairer; Howard D Sesso; Tracey G Simon; Rashmi Sinha; Rachael Z Stolzenberg-Solomon; Shoichiro Tsugane; Renwei Wang; Elisabete Weiderpass; Stephanie J Weinstein; Emily White; Alicja Wolk; Jian-Min Yuan; Anne Zeleniuch-Jacquotte; Xuehong Zhang; Katherine A McGlynn; Peter T Campbell; Jill Koshiol
Journal:  Cancer Res       Date:  2019-05-21       Impact factor: 12.701

2.  Challenges in elucidating cholangiocarcinoma etiology.

Authors:  Sarah S Jackson; Andrea A Florio; Katherine A McGlynn; Jessica L Petrick
Journal:  Hepatobiliary Surg Nutr       Date:  2020-08       Impact factor: 7.293

3.  Associations between reproductive factors and biliary tract cancers in women from the Biliary Tract Cancers Pooling Project.

Authors:  Sarah S Jackson; Hans-Olov Adami; Gabriella Andreotti; Laura E Beane-Freeman; Amy Berrington de González; Julie E Buring; Gary E Fraser; Neal D Freedman; Susan M Gapstur; Gretchen Gierach; Graham G Giles; Francine Grodstein; Patricia Hartge; Mazda Jenab; Victoria Kirsh; Synnove F Knutsen; Qing Lan; Susanna C Larsson; I-Min Lee; Mei-Hsuan Lee; Linda M Liao; Roger L Milne; Kristine R Monroe; Marian L Neuhouser; Katie M O'Brien; Jessica L Petrick; Mark P Purdue; Thomas E Rohan; Sven Sandin; Dale P Sandler; Norie Sawada; Aladdin H Shadyab; Tracey G Simon; Rashmi Sinha; Rachael Stolzenberg-Solomon; Shoichiro Tsugane; Elisabete Weiderpass; Alicja Wolk; Hwai-I Yang; Wei Zheng; Katherine A McGlynn; Peter T Campbell; Jill Koshiol
Journal:  J Hepatol       Date:  2020-05-11       Impact factor: 25.083

Review 4.  Excess Body Weight and Gastrointestinal Cancer Risk.

Authors:  Hans Scherübl
Journal:  Visc Med       Date:  2021-04-13

Review 5.  Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma.

Authors:  Xing Chen; Jinpeng Du; Jiwei Huang; Yong Zeng; Kefei Yuan
Journal:  J Clin Transl Hepatol       Date:  2022-01-04

6.  Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review.

Authors:  Audra N Boscoe; Catherine Rolland; Robin Kate Kelley
Journal:  J Gastrointest Oncol       Date:  2019-08

7.  Diabetes and liver cancer risk: A stronger effect in Whites than Blacks?

Authors:  Rebecca Baqiyyah N Conway; Staci Sudenga; Donald McClain; William J Blot
Journal:  J Diabetes Complications       Date:  2020-12-01       Impact factor: 2.852

Review 8.  Liquid biopsy in cholangiocarcinoma: Current status and future perspectives.

Authors:  Gianluca Rompianesi; Marcello Di Martino; Alex Gordon-Weeks; Roberto Montalti; Roberto Troisi
Journal:  World J Gastrointest Oncol       Date:  2021-05-15

Review 9.  ARID1A Variations in Cholangiocarcinoma: Clinical Significances and Molecular Mechanisms.

Authors:  Shankun Zhao; Youwen Xu; Weizhou Wu; Pan Wang; Yichao Wang; Hao Jiang; Jie Zhu
Journal:  Front Oncol       Date:  2021-06-25       Impact factor: 6.244

10.  Abdominal and gluteofemoral size and risk of liver cancer: The liver cancer pooling project.

Authors:  Andrea A Florio; Peter T Campbell; Xuehong Zhang; Anne Zeleniuch-Jacquotte; Jean Wactawski-Wende; Stephanie A Smith-Warner; Rashmi Sinha; Tracey G Simon; Howard D Sesso; Catherine Schairer; Lynn Rosenberg; Thomas E Rohan; Kim Robien; Andrew G Renehan; Mark P Purdue; Jenny N Poynter; Julie R Palmer; Christina C Newton; Yunxia Lu; Martha S Linet; Linda M Liao; I-Min Lee; Jill Koshiol; Cari M Kitahara; Victoria A Kirsh; Jonathan N Hofmann; Barry I Graubard; Edward Giovannucci; John M Gaziano; Susan M Gapstur; Neal D Freedman; Jane Demuth; Dawn Q Chong; Andrew T Chan; Julie E Buring; Patrick T Bradshaw; Laura E Beane Freeman; Katherine A McGlynn; Jessica L Petrick
Journal:  Int J Cancer       Date:  2019-12-23       Impact factor: 7.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.